Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Glucotrack subsidiary Lōkahi Therapeutics announced its first external fee-for-service engagement for the ai² PIPELINE platform, with nonprofit Innovate GBM sponsoring two project teams to identify brain tumor therapeutic assets. The deal marks the platform's transition from an internal discovery engine to a revenue-generating service model, supported by 14 existing university collaborations. Innovate GBM will independently decide whether to license any identified assets; Lōkahi positions the sponsor-led model as extensible to pharma, biotech, and investment organizations.
Key figures
- First external sponsor
- Innovate GBM
- University collaborations
- 14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.